Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Expert Insights on Oncology

Oncology is the field of medicine dealing with tumors (cancer), including their biology, prevention, diagnosis, and treatment. Cancer biology focuses on the mechanisms for abnormal cell growth and tumor metastasis; diagnosis involves biopsy, endoscopy, radiological imaging, nuclear medicine, and blood tests for tumor markers; prevention includes genetic testing, education, and screening; therapies like surgery, chemotherapy, and radiation therapy aim to inhibit tumor development.

Gerson Lehrman Group Council Members are available to discuss Oncology via phone consultations, live meetings, surveys, and other custom GLG products and services.

Find, engage, and manageSM experts today through the GLG platform

Featured Council Members

GLG Council Members are leading experts including academics, scientists, and industry specialists

Donald Fleming, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Donald FlemingWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Division Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC

Brian Abbott, Medical Director of Hematology, Big Sky Oncology

Brian AbbottWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Medical Director of HematologyBig Sky Oncology

Haitham Al-Okk, Assistant Clinical Professor - Hematology-Oncology, Mahr Cancer Center

Haitham Al-OkkWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Assistant Clinical Professor - Hematology-OncologyMahr Cancer Center

Taral Patel, Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INC

Taral PatelWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

OncologistMID-OHIO ONCOLOGY & HEMOTOLOGY INC

Charles Bennett, Radiation Oncologist , ROBERT BOISSONEAULT ONCOLOGY INSTITUTE

Charles BennettWhat is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Radiation Oncologist ROBERT BOISSONEAULT ONCOLOGY INSTITUTE

Browse all 420 Leading Experts

Study Groups

Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry

Study Group Name No. Members
Oncology Devices Distributors 25
Oncology Reimbursement Experts (US) 112
Oncology Physicians who Treat CID (US) 23
Cardiology Device Distributors 70
Gastroenterology Devices Distributors 40

Browse all 974 Study Groups

Recent Live Meetings

Interactive roundtables, private visits, and small scale seminars are types of GLG Live Meetings

November 20, 2009 | San Francisco

Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD

November 12, 2009 | Boston

Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD (Boston)

November 13, 2009 | New York

Seminar: Issues in Using PFS when Evaluating Oncology Products with Thomas Fleming, PhD (New York)

Browse all 278 Live Meetings

Recent News Analyses

News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations

ASTRO/ACRO help win the fight against Reimbursement Cuts for Radiation Oncology

November 2, 2009

GLG Expert Contributor

Roche's Avastin declined by European "bean counters" for brain tumor

November 23, 2009

Donald Fleming, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Omapro will fill a CML void

November 14, 2009

Donald Fleming, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Particle Beam Technology - Costly and a limited utility

October 26, 2009

Jon Strasser, Assistant Professor of Radiation Oncology, THOMAS JEFFERSON UNIVERSITY

Triple negative Breast Cancer Strategies

October 14, 2009

Donald Fleming, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Browse all 7858 GLG News Analyses

Contact Gerson Lehrman Group to engage a Oncology expert